If you typed NZCR Group (NZCR + Optimal Clinical Trials) into a search box, you’re probably building a shortlist for a trial in New Zealand. This article uses only what NZCR publishes (nzcr.co.nz, NZCR facilities and services, optimalclinicaltrials.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It’s a practitioner comparison, not a teardown.
What NZCR publishes
NZCR calls itself “New Zealand’s leading early-phase clinical research provider”. It says it has 35+ years of experience, has run 800+ trials with 17,000+ New Zealanders, and has 81 research beds. Its dosing units are in Auckland and Christchurch, with support sites in Hamilton and Wellington, and the units are Medsafe-certified under section 30 of the Medicines Act. Its sister company, Optimal Clinical Trials, focuses on late-phase work. Optimal describes the “NZCR Group” as “Australasia’s largest clinical trials group”. It claims “fast start-ups (4–6 weeks, no IND requirement)”, ISO 9001 certification, access to about 75% of New Zealand’s primary-care database, and a patient pool of 153,000+. It also says it is a government-approved R&D incentives provider and a “proven rescue site”. We found no named medical-device first-in-human study on the pages we reviewed.
NZCR vs bioaccess®
| Dimension | NZCR | bioaccess® |
|---|---|---|
| Core focus | Drug Phase I units (NZCR) plus late-phase sites (Optimal) | First-in-human and early feasibility studies for medical devices |
| Geography | New Zealand (Auckland, Christchurch, Hamilton, Wellington) | Latin America, since 2010 |
| Device FIH track record | None named on the public pages we reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Multi-country sanitary registration and in-country holder service |
Where each one fits
If you are running a healthy-volunteer or patient Phase I drug study and want overnight beds in New Zealand, NZCR is a serious option. Optimal’s primary-care reach suits large late-phase recruitment.
If the job is a first-in-human or early feasibility study for a medical device, and especially one that needs more patients than one small country can supply, bioaccess® was built for exactly that. It has run device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including NZCR, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan, and how the data was used in an FDA file.
New Zealand offers real country advantages:
– device trials need HDEC ethics approval but no Medsafe approval;
– one ethics review covers all sites;
– HDEC aims to decide within 15 days (expedited review) or 35 days (full review).
Those advantages belong to the country, not to NZCR. New Zealand also has about 5.36 million people, and commercial sponsors must provide ACC-equivalent injury compensation. We set out the country comparison in New Zealand vs Latin America for first-in-human device trials and bioaccess® vs New Zealand.
Frequently asked questions
Does NZCR run medical device first-in-human studies?
NZCR’s public pages describe drug early-phase units and services. We found no named device first-in-human study there. Ask NZCR directly for device examples.
Does a device trial in New Zealand need Medsafe approval?
No. Under the Medicines Act 1981 there is no provision to require approval of device trials. Medsafe asks to be notified, and HDEC ethics approval is required (Medsafe guideline, §7).
Can Latin American device data support an FDA submission?
Yes. Foreign device data is eligible for FDA review under 21 CFR 812.28 when GCP, independent ethics review and informed consent are met, and FDA can validate the data. Eligibility isn’t clearance or approval.
When is bioaccess® the better choice than NZCR?
When the study is a device first-in-human or early feasibility study, needs a second country or more patients, or needs U.S.-adjacent time zones and a route to registration in Latin America.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts come from the NZCR public pages linked above, reviewed 28 October 2026 for bioaccess® competitive research. The claims are theirs. No sponsors, prices or contacts are invented.